Darlene Dobkowski, MA

Guidelines often use a cutoff of 70 years old for breast cancer treatment, but patients should discuss goals of care with their team to further personalize their care.

The Food and Drug Administration approved Trodelvy for patients with pretreated, unresectable HR-positive, HER2-negative metastatic breast cancer.

Since 2015, the use of immunotherapies has increased for both young and older patients, but the survival benefit is more evident in younger patients, findings demonstrated.

In this episode of the “Cancer Horizons” podcast, “Rabbi G” discusses his global travels to teach breathwork to children with cancer, and gives an exercise listeners can use to decrease their pain and anxiety.

Older patients with advanced cancer who were taking eight or more medications before starting treatment were more likely to discontinue treatment and/or experience a side effect from drug interactions.

The TRANSCNED CLL 004 trial met its primary endpoint of complete responses with the CAR-T cell therapy Breyanzi in patients with relapsed or refractory CLL or SLL.

Women with low-grade serous ovarian cancer treated with avutometinib and defactinib experienced positive response rates compared with avutometinib alone.

An expert from the FDA explained the benefits and limitations of these two clinical trial formats and how the cancer field can learn from both.

A data monitoring committee recommended to stop the phase 3 trial in metastatic hormone-sensitive prostate cancer due to a lack of progression-free survival and overall survival with combination therapy.

As more news is released about studies assessing cancer vaccines, one expert explains what this may mean for patients in the future.

Although patients with cancer may feel both grateful and grief towards their bodies, one expert emphasizes how important seeking support from a professional can be throughout this process.

The FDA recently approved a combination treatment for patients with previously treated metastatic colorectal cancer with HER2-positive disease determined by biomarker testing.

Skin cancer can also occur in the nail area and may be associated with HPV, it may not be as common for it to result from a cut experienced during a manicure, one expert explained.

Patients undergoing surgery for gynecologic cancer may benefit from acupressure, acupuncture and other relaxation techniques regarding pain relief and a reduction in anxiety.

An oncolytic virus engineered to kill cancer cells was administered to a patient with pancreatic ductal adenocarcinoma as part of a phase 2b trial.

Patients with operable non-small cell lung cancer who were treated with an anti-PD-1 monoclonal antibody plus a doublet chemotherapy regiment did not experience cancer recurrence or new symptom onset during follow-up in a recent study.

Women who were taking beta-blockers, a medicine to treat heart conditions like high blood pressure, among others, near the time of surgery for epithelial ovarian cancer may confer a survival benefit years after undergoing a procedure.

As young adults, survivors of childhood cancers were more likely to report feeling lonely compared with their siblings, emphasizing the importance of screening.

The injection Lumoxiti, which was approved for patients with relapsed or refractory hairy cell leukemia, will be pulled from the U.S. market later this year, although alternative therapies are available.

Testicular cancer survivors who were treated with cisplatin-based chemotherapy may have hearing loss or ringing of the ears, which may significantly affect certain parts of life including sleep and concentration, among other factors.

The risk for psychiatric disorders increased for spouses of patients with cancer compared with those whose partners did not have cancer.

One patient describes the management of symptoms of graft-versus-host disease as playing Whac-a-Mole and emphasizes the importance of awareness and education for both patients and their families.

From prostate cancer to disease spread in the brain, one patient learned how to recognize how far he has come since his journey began.

One expert explains how the road to cancer drug development isn’t a smooth one, but progress can be made nonetheless.

FDA-approved immunotherapies offer patients with metastatic or recurrent sarcomatoid RCC more treatment choices and improved outcomes.

Patients with relapsed/refractory follicular lymphoma — a group that traditionally has limited treatment options — now have a new bispecific antibody available.

A childhood cancer survivor now works raising funds for Children’s Hospital of Philadelphia, the same hospital where she received treatment for Ewing sarcoma at 12 years old.

The indication for Pemfexy has been approved to include patients with metastatic, non-squamous, non-small cell lung cancer without EGFR or ALK genomic tumor mutations.

Adults with graft-versus-host disease who were treated with a three-drug regimen with cyclophosphamide after transplant may have improved survival rate compared with those treated with a two-drug regimen.

Adstiladrin represents the first gene therapy approved by the FDA for the treatment of patients with high-risk non-muscle invasive bladder cancer who are resistant to BCG, the first-line standard of care for these patients.